Comparison of electropharmacological effects of bepridil and sotalol in halothane-anesthetized dogs

Circulation Journal

Volumn 72, Issue 6, 2008, Pages 1003-1011

  Ishizaka, Tomomichi ^a,b   Takahara, Akira ^a   Iwasaki, Hiroshi ^a   Mitsumori, Yoshitaka ^a   Kise, Hiroaki ^a   Nakamura, Yuji ^a   Sugiyama, Atsushi ^a,b  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b Yamanashi Research Center of Clinical Pharmacology   (Japan)

Author keywords

Bepridil; dl Sotalol; Electrophysiological effects; Hemodynamics

Indexed keywords

BEPRICOR; BEPRIDIL; HALOTHANE; HEPARIN CALCIUM; ISOPRENALINE; SOTALOL; THIOPENTAL;

ANESTHESIA; ANIMAL EXPERIMENT; ARTICLE; ATRIOVENTRICULAR CONDUCTION; BLOOD PRESSURE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; HEART MUSCLE POTENTIAL; HEART MUSCLE REFRACTORY PERIOD; HEART VENTRICLE CONTRACTION; NONHUMAN;

ADRENERGIC BETA-ANTAGONISTS; ANESTHETICS, INHALATION; ANIMALS; ATRIOVENTRICULAR NODE; BEPRIDIL; BUNDLE OF HIS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HALOTHANE; HEART CONDUCTION SYSTEM; MALE; MODELS, ANIMAL; MYOCARDIAL CONTRACTION; PACEMAKER, ARTIFICIAL; SINOATRIAL NODE; SOTALOL; VASODILATOR AGENTS;

EID: 45849140484     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.72.1003     Document Type: Article

References (46)

1. Hill JA, O'Brien JT, Scott E, Conti CR, Pepine CJ. Effects of bepridil on exercise tolerance in chronic stable angina: A double-blind, randomized, placebo-controlled, crossover trial. Am J Cardiol 1984; 53: 679-683.
2. Verdouw PD, Scheffer MG. Cardiovascular actions after intravenous and intracoronary administration of the slow channel blocker bepridil. Arzneimittelforschung 1984; 34: 21-25.
3. Anno T, Furuta T, Itoh M, Kodama I, Toyama J, Yamada K. Electromechanical effects of bepridil on rabbit isolated hearts. Br J Pharmacol 1984; 81: 41-47.
4. Sassine A, Masse C, Fajuri A, Hirsch JL, Labrid C, Puech P. Electrophysiologic effects of bepridil in the anesthetized dog studied by endocardiac electrodes. Am. J Cardiol 1984; 53: 1707-1711.
5. Yatani A, Brown AM, Schwartz A. Bepridil block of cardiac calcium and sodium channels. J Pharmacol Exp Ther 1986; 237: 9-17.
6. + currents, IKr and IKs, in guinea-pig ventricular myocytes. Br J Pharmacol 1999; 128: 1733-1738.
7. Yoshida T, Niwano S, Inuo K, Saito J, Kojima J, Ikeda-Murakami K, et al. Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect. Pacing Clin Electrophysiol 2003; 26: 314-317.
8. Yoshida T, Niwano S, Inuo K, Saito J, Kojima J, Ikeda-Murakami K, et al. Evaluation of the effect of bepridil on paroxysmal atrial fibrillation: Relationship between efficacy and the f-f interval in surface ECG recordings. Circ J 2003; 67: 11-15.
9. Nakazato Y, Yasuda M, Sasaki A, Iida Y, Kawano Y, Nakazato K et al. Conversion and maintenance of sinus rhythm by bepridil in patients with persistent atrial fibrillation. Circ J 2005; 69: 44-48.
10. Fujiki A, Tsuneda T, Sugao M, Mizumaki K, Inoue H. Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm. Am J Cardiol 2003; 92: 472-475.
11. Izumi D, Chinushi M, Watanabe H, Washizuka T, Okamura K, Komura S, et al. Bepridil for drug-refractory ventricular tachyarrhythmias. Intern Med 2007; 46: 119-124.
12. Kobayashi S, Reien Y, Ogura T, Saito T, Masuda Y, Nakaya H. Inhibitory effect of bepridil on hKv1.5 channel current: Comparison with amiodarone and E-4031. Eur J Pharmacol 2001; 430: 149-157.
13. Berger F, Borchard U, Hafner D. Effects of the calcium entry blocker bepridil on repolarizing and pacemaker currents in sheep cardiac Purkinje fibres. Naunyn Schmiedebergs Arch Pharmacol 1989; 339: 638-646.
14. Hara Y, Nakaya H. SD-3212, a new class I and IV antiarrhythmic drug: A potent inhibitor of the muscarinic acetylcholine receptor-operated potassium current in guinea-pig atrial cells. Br J Pharmacol 1995; 116: 2750-2756.
15. Kantelip JP, Alatienne M, Talmant JM, Ghyselinck N, Duchene-Marullaz P. Comparative electrophysiologic effects of bepridil, verapamil and diltiazem in conscious and anesthetized dogs. Arch Int Pharmacodyn Ther 1986; 284: 5-18.
16. Leboeuf J, Lamar JC, Massingham R, Ponsonnaille J. Electrophysiological effects of bepridil and its quaternary derivative CERM 11888 in closed chest anaesthetized dogs: A comparison with verapamil and diltiazem. Br J Pharmacol 1989; 98: 1351-1359.
17. Antonaccio MJ, Gomoll A. Pharmacologic basis of the antiarrhythmic and hemodynamic effects of sotalol. Am J Cardiol 1993; 72: 27A-37A.
18. Anderson JL, Prystowsky EN. Sotalol: An important new antiarrhythmic. Am Heart J 1999; 137: 388-409.
19. Ando K, Sugiyama A, Takahara A, Satoh Y, Ishizaka T, Nakamura Y, et al. Analysis of proarrhythmic potential of antipsychotics risperidone and olanzapine in anesthetized dogs. Eur J Pharmacol 2007; 558: 151-158.
20. Satoh Y, Sugiyama A, Takahara A, Ando K, Wang K, Honsho S, et al. The antipsychotic and antiemetic drug prochlorperazine delays the ventricular repolarization of the in situ canine heart. J Pharmacol Sci 2005; 97: 101-106.
21. Shiina H, Sugiyama A, Takahara A, Satoh Y, Hashimoto K. Comparison of the electropharmacological effects of verapamil and propranolol in the halothane-anesthetized in vivo canine model under monophasic action potential monitoring. Jpn Circ J 2000; 64: 777-782.
22. Sugiyama A, Takahara A, Hashimoto K. Electrophysiologic, cardiohemodynamic and β-blocking actions of a new ultra-short-acting β-blocker, ONO-1101, assessed by the in vivo canine model in comparison with esmolol. J Cardiovasc Pharmacol 1999; 34: 70-77.
23. Takahara A, Sugiyama A, Satoh Y, Wang K, Honsho S, Hashimoto K. Halothane sensitizes the canine heart to pharmacological IKr blockade. Eur J Pharmacol 2005; 507: 169-177.
24. Yoshida H, Sugiyama A, Satoh Y, Ishida Y, Kugiyama K, Hashimoto K. Effects of disopyramide and mexiletine on the terminal repolarization process of the in situ heart assessed using the halothane-anesthetized in vivo canine model. Circ J 2002; 66: 857-862.
25. Bazett HC. An analysis of the time-relations of electrocardiogram. Heart 1920; 7: 353-370.
26. Van de Water A, Verheyen J, Xhonneux R, Reneman RS. An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. J Pharmacol Methods 1989; 22: 207-217.
27. Sugiyama A, Hashimoto K. Effects of a typical IKr channel blocker sematilide on the relationship between ventricular repolarization, refractoriness and onset of torsades de pointes. Jpn J Pharmacol 2002; 88: 414-421.
28. Omata T, Kasai C, Hashimoto M, Hombo T, Yamamoto K. QT PRODACT: Comparison of non-clinical studies for drug-induced delay in ventricular repolarization and their role in safety evaluation in humans. J Pharmacol Sci 2005; 99: 531-541.
29. Suzuki H, Itoh T, Kuriyama H. Mechanisms of the bepridil-induced vasodilation of the rabbit mesenteric artery. J Pharmacol Exp Ther 1985; 235: 749-756.
30. Takahara A, Sugiyama A, Satoh Y, Yoneyama M, Hashimoto K. Cardiovascular effects of Y-27632, a selective Rho-associated kinase inhibitor, assessed in the halothane-anesthetized canine model. Eur J Pharmacol 2003; 460: 51-57.
31. 2+ channel blocker cilnidipine in anesthetized dogs. Eur J Pharmacol 2007; 565: 166-170.
32. Nobe S, Aomine M, Arita M. Bepridil prolongs the action potential duration of guinea pig ventricular muscle only at rapid rates of stimulation. Gen Pharmacol 1993; 24: 1187-1196.
33. Ozaki H, Zaizen H, Kiyosue T, Nasu M, Arita M. Effect of bepridil on intracellular calcium concentration and contraction in cultured rat ventricular myocytes. J Cardiovasc Pharmacol 1999; 33: 492-499.
34. Cohen CJ, Spires S, Van Skiver D. Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol 1992; 100: 703-728.
35. 2+ channel by bepridil. Pharmacology 2005; 74: 174-181.
36. Satoh Y, Sugiyama A, Tamura K, Hashimoto K. Effects of a class III antiarrhythmic drug, dofetilide, on the in situ canine heart assessed by the simultaneous monitoring of hemodynamic and electrophysiological parameters. Jpn J Pharmacol 1999; 81: 79-85.
37. Nawada T, Tanaka Y, Hisatome I, Sasaki N, Ohtahara A, Kotake H, et al. Mechanism of inhibition of the sodium current by bepridil in guinea-pig isolated ventricular cells. Br J Pharmacol 1995; 116: 1775-1780.
38. + channel by bepridil in isolated guinea-pig ventricular myocytes. Eur J Pharmacol 1996; 314: 373-379.
39. Takahara A, Sugiyama A, Satoh Y, Hashimoto K. Effects of mexiletine on the canine model of sparfloxacin-induced long QT syndrome. Eur J Pharmacol 2003; 476: 115-122.
40. Kawada M, Satoh K, Taira N. Profile of coronary vasodilator and cardiac actions of bepridil revealed by use of isolated, blood-perfused heart preparations of the dog. J Cardiovasc Pharmacol 1983; 5: 604-612.
41. Komori S, Ishii M, Hashimoto K. Antiarrhythmic effects of coronary vasodilators on canine ventricular arrhythmia models. Jpn J Pharmacol 1985; 38: 73-82.
42. Ducroq J, Printemps R, Guilbot S, Gardette J, Salvetat C, Le Grand M. Action potential experiments complete hERG assay and QT interval measurements in cardiac preclinical studies. J Pharmacol Toxicol Methods 2007; 56: 159-170.
43. Satoh Y, Sugiyama A, Takahara A, Chiba K, Hashimoto K. Electropharmacological and proarrhythmic effects of a class III antiarrhythmic drug nifekalant hydrochloride assessed using the in vivo canine models. J Cardiovasc Pharmacol 2004; 43: 715-723.
44. So PP, Hu XD, Backx PH, Puglisi JL, Dorian P. Blockade of IKs by HMR 1556 increases the reverse rate-dependence of refractoriness prolongation by dofetilide in isolated rabbit ventricles. Br J Pharmacol 2006; 148: 255-263.
45. Sugiyama A, Satoh Y, Hashimoto K. Acute electropharmacological effects of intravenously administered amiodarone assessed in the in vivo canine model. Jpn J Pharmacol 2001; 87: 74-82.
46. Nair LA, Grant AO. Emerging class III antiarrhythmic agents: Mechanism of action and proarrhythmic potential. Cardiovasc Drugs Ther 1997; 11: 149-167.